Recently,As the first of the top ten key tasks of the group in 2023, iopamol injection (consistency evaluation).100 ml: 30 g (I) and 37 g (IML: 27.)75 g (i) and 50 ml: 185g(i)，Approved by the State Food and Drug Administration, it is deemed to have passed the consistency evaluation. of which 75ml: 2775g(i) is the exclusive specification in China. This is the first production approval approved by Consun Pharmaceutical Group in the past five years, which is a milestone for the future development of the group's imaging line.
Figure |Notification of ApprovalThis is also the first approved approval document after the rebuilding of the R&D system of Consun Pharmaceutical Group, which proves the growth of the Group's drug research center and the strength of generic drug R&D projects, pharmaceutical R&D, and registration declaration. Through close cooperation with various departments such as production center and logistics center, the Group's Pharmaceutical Research Center has improved the ability of technology transfer such as pilot test and process verification of new products, which not only provides a new starting point for the marketing, marketing and team shaping and development of imaging products, but also expands the value space for the future development of Consun Pharmaceutical Group for the capital market.
From September 2019, Li Qian, the founder, vice chairman of the board of directors and CEO of the group, approved the project establishment, the establishment of the project team, the search and negotiation of APIs, the transformation and optimization of the production line, the small-scale pilot test, the production verification, the special safety test, the stability study, the registration declaration, and the supplementary research, after more than 1,500 days of hard work, hardship, persistence, waiting and even suffering, and finally handed over a satisfactory answer. The entire project team fully demonstrated the core values of Consun Pharmaceutical with practical actions"Human-oriented, sincere, responsible, sharing"., as well as the spirit of enterprise"Passion ignites dreams, struggle achieves life".
Figure |Group photo of the project team members.
The approval of the 4 specifications of the consistency evaluation of iopamol injection is the end point and the starting point, a small step and a big step!I believe that under the correct leadership of the group leaders, there will be more Kangsun Pharmaceutical Group in the future"High-tech, high-efficiency, high-quality".In addition, the launch of new products with market competitiveness will help the group achieve the strategic goal of double hundred, give back to the society and benefit the people.